Tempus AI, Inc.
TEM
주식 순위
#1866
Tempus AI, Inc. operates as a healthcare technology company in the United... Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
주가
$64.74
마지막 동기화: 2026-10-19
시가총액
$11.35B
변동 (1일)
0.03%
변동 (1년)
-29.97%
국가
US
거래 Tempus AI, Inc. (TEM)
카테고리
Healthcare
Tempus AI, Inc. (TEM)의 P/E 비율
October 2026 기준 P/E 비율 TTM: -47.78
Tempus AI, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 -47.78입니다. 2023년 말 기준 P/E 비율은 -30.05였습니다.
Tempus AI, Inc.의 P/E 비율 기록 (2019 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | -47.78 | 516.47% |
| 2024 | -7.75 | -74.20% |
| 2023 | -30.05 | 27.39% |
| 2022 | -23.59 | -10.57% |
| 2021 | -26.38 | -19.04% |
| 2020 | -32.58 | -42.10% |
| 2019 | -56.27 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 19.68 | -141.18% |
US
|
|
| 64.40 | -234.80% |
AU
|
|
| 44.30 | -192.73% |
US
|
|
| -123.90 | 159.33% |
US
|
|
| - | - |
US
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.